Cannabigerol - CBG properties

In our store you will find CBD+ hemp oils CBG.  These are full spectrum oils, i.e. those that contain most of the beneficial compounds contained in the whole plant. As you know, hemp contains well over 100 different cannabinoids, as well as terpenes, flavonoids and antioxidants. CBD or cannabidiol is the best-studied cannabinoid so far, but such research is still ongoing, and new ideas are being born. You will read about CBD here. CBG or cannabigerol is another non-psychoactive hemp compound that scientists and doctors have become interested in. As quickly as CBD oils, the hemp market was flooded with CBG oils. What is CBG and what has been proven to be the effect of this compound on the human body? You will find the answers to these questions below.

CBG cannabinoid metabolic pathway

CBGA cannabinoid metabolic pathway [9]

What is CBG?

CBG i.e. cannabigerol is a hemp cannabinoid that does not show psychoactive properties. Interesting information is that the acidic form of CBG can be transformed into the acidic forms of CBDA and THCA, but also into the acids of other phytocannabinoids contained in hemp. It is from the acidic forms, i.e. CBDA, THCA or CBGA, under the influence of heat, the active forms of cannabidnoids are formed, i.e. CBD, THC and CBG, respectively. Cannabigerol is therefore a precursor to the formation of other cannabinoids. In animal studies, CBG turned out to be safe, due to the lack of side effects, and due to the good tolerance of this compound in the tested animals. [1] The research results so far show that CBG, similarly to CBD, affects the endocannabinoid system, specifically the effect on CB1 receptors. The effect of this is to reduce the psychoactive effect of THC on the human body.

Many varieties of hemp are characterized by the content of cannabigerol, in the absence of tetrahydrocannabinol or its trace, allowed amounts. CBG remains legal as an ingredient in hemp extracts that do not exceed 0,2% THC.


CBG Properties:

Although the number of studies on the impact of CBG on the human body is still inexhaustible and will probably remain so for a long time, we already know a little about this compound and its potential in the treatment or supporting the treatment of many diseases. From the research published so far, we can learn that CBG has the following properties:


Previous research indicates the great therapeutic potential of CBG in the treatment of various disorderseurbiological diseases, e.g. Parkinson's disease, Huntington's disease or multiple sclerosis.

The effectiveness of cannabigerol has also been demonstrated in Epilepsy models.[2]


The potential of CBG has been demonstrated, e.g. in the treatment of inflammatory bowel disease. A study in rodents showed that cannabigerol attenuated colitis. [3]

There is also a study that found the potential of CBG in treating neuroinflammation and oxidative stress. Inflammation and oxidative stress play a major role ineurdegeneration. [4]


The bacteriostatic and bactericidal effect of cannabigerol on the s. Mutans bacteria has been demonstrated. Thus, CBG may be a potential drug in the prevention of tooth decay, which is caused by, among others, mentioned bacteria. [5]

CBD and THC are known to have antibacterial properties. Similarly with other main cannabinoids, i.e. Cannabinol, cannabichromene, but also cannabigerol, which together with CBD and THC have a strong effect, e.g. against various strains of methicillin-resistant Staphylococcus aureus. [6]


CBG has been shown to protect against colorectal cancer in laboratory studies. The in vivo antitumor effect of CBG was evaluated in murine colon cancer models. They found that CBG inhibited the development of colon cancer and selectively inhibited the growth of colorectal cancer (CRC) cells. [7]

There is a study that found that CBG was effective in attenuating the essential features of the development of glioblastoma, the most aggressive of the primary brain tumors. [8]  So far, in the case of Glioma, a combination of CBD and THC has been used, but it was decided to check the effects of CBD and CBG. The psychoactive effects of tetrahydrocannabinol are harmful in patients with glioblastoma multiforme,eurbiological factors related to the development of this cancer. It turned out that, in addition to its clear anticancer effect, the combination of CBG and CBD has a palliative effect, i.e. analgesia (relief of pain), appetite and prevention of significant weight loss and nausea caused by chemotherapy.


More than 30 years ago, researchers showed that CBG has an analgesic effect. This is because it has a strong antioxidant effect and reduces inflammation in the body. The same is the case with CBD, which is why both cannabinoids are considered and tested, among others. for the treatment of pain neurogenic. There is also a question whether the combination of CBD and CBG will allow the creation of painkillers without psychoactive THC.


It turns out that cannabigerol can have a calming and anti-anxiety effect. CBG works on a similar principle to some drugs used for epilepsy, namely it reduces the reuptake of gamma-aminobutyric acid (GABA). GABA is neura transmitter that inhibits the activity of neurhe. As a result, its level in the brain is increased, which causes a calming and muscle relaxation effect.

The interaction of CBG with presynaptic receptors located, among others, in the in the cerebral cortex and brainstem. The effect of which is a sleeping and sedative effect, as well as a blood pressure lowering effect. The intraocular pressure-lowering effect of CBG has been found to be extremely beneficial in supporting the treatment of glaucoma.


 In preclinical studies, cannabigerol has been shown to prevent nausea and relieve gag reflexes.

Contraindications to the use of CBG:

We wrote about the contraindications of using CBD here. In the case of CBG, the situation is very similar, as both cannabinoids are metabolized by the same liver enzymes. Everything we eat can interact with the medications we are currently taking. More than half of the drugs are metabolized by the same liver enzymes, so you should watch the impact of the cannabinoids you take on your body and choose the right dose for you. As in the case of CBD, CBG can enhance the effects of medications taken, as well as reduce their effectiveness.

   CBG Properties | cannabigerol 


  1. Brierley DI, Samuels J, Duncan M, Whalley BJ, Williams CM. Cannabigerol is a novel, well-tolerated appetite stimulant in pre-saturated rats. Psychopharmacology (Berl) . 2016;233(19-20):3603-3613. doi:10.1007/s00213-016-4397-4
  2. Stone NL, Murphy AJ, England TJ, O'Sullivan SE. A systematic review of minor phytocannabinoids with promising neurprotective potential. Br J Pharmacol. 2020 Oct;177(19):4330-4352. doi: 10.1111/bph.15185. Epub 2020 Sep 1. PMID: 32608035; PMCID: PMC7484504.
  3. Borrelli F, Fasolino I, Romano B, Capasso R, Maiello F, Coppola D, Orlando P, Battista G, Pagano E, Di Marzo V, Izzo AA. Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. Biochem Pharmacol. 2013 May 1;85(9):1306-16. doi: 10.1016/j.bcp.2013.01.017. Epub 2013 Feb 12. PMID: 23415610.
  4. Gugliandolo A, Pollastro F, Grassi G, Bramanti P, Mazzon E. In Vitro Model of Neuroinflammation: Efficacy of Cannabigerol, a Non-Psychoactive Cannabinoid. Int J Mol Sci. 2018 Jul 8;19(7):1992. doi: 10.3390/ijms19071992. PMID: 29986533; PMCID: PMC6073490.
  5. Aqawi M, Sionov RV, Gallily R, Friedman M, Steinberg D. Anti-Biofilm Activity of Cannabigerol against Streptococcus mutans. microorganisms. 2021 Sep 25;9(10):2031. doi: 10.3390/microorganisms9102031. PMID: 34683353; PMCID: PMC8539625.
  6. Antibacterial Cannabinoids from Cannabis sativa: A Structure-Activity Study Giovanni Appendino, Simon Gibbons, Anna Giana, Alberto Pagani, Gianpaolo Grassi, Michael Stavri, Eileen Smith, and M. Mukhlesur RahmanJournal of Natural Products 2008 71 (8), 1427-1430 DOI: 10.1021/np8002673
  7. Borrelli F, Pagano E, Romano B, Panzera S, Maiello F, Coppola D, De Petrocellis L, Buono L, Orlando P, Izzo AA. Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a Cannabis-derived non-psychotropic cannabinoid. Carcinogenesis. 2014 Dec;35(12):2787-97. doi: 10.1093/carcin/bgu205. Epub 2014 Sep 30. PMID: 25269802.
  8. Lah TT, Novak M, Pena Almidon MA, et al. Cannabigerol Is a Potential Therapeutic Agent in a Novel Combined Therapy for Glioblastoma. Cells. Cells.. 2021;10(2):340. Published 2021 Feb 5. doi:10.3390/cells10020340

Leave a comment

Leave a comment